Investing.com - LeMaitre Vascular (NASDAQ: LMAT) reported fourth quarter EPS of $0.25, $0.01 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $41M versus the consensus estimate of $41M.
Guidance
LeMaitre Vascular sees Q1 2023 EPS of $0.22-$0.27 versus the analyst consensus of $0.27.
LeMaitre Vascular sees Q1 2023 revenue of $42.60M-$45.00M versus the analyst consensus of $41.60M.
LeMaitre Vascular sees FY 2023 EPS of $1.11-$1.20 versus the analyst consensus of $1.19.
LeMaitre Vascular sees FY 2023 revenue of $174.30M-$178.30M versus the analyst consensus of $171.40M.
LeMaitre Vascular's stock price closed at $48.31. It is up 4.66% in the last 3 months and up 6.30% in the last 12 months.
LeMaitre Vascular saw 0 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See LeMaitre Vascular's stock price’s past reactions to earnings here.
According to InvestingPro, LeMaitre Vascular's Financial Health score is "great performance".
Check out LeMaitre Vascular's recent earnings performance, and LeMaitre Vascular's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar